Animal-welfare groups are concerned that a new report from the European Chemicals Agency on the regulatory applicability of alternative tests "weighs too heavily on the challenges faced in applying data from non-animal methods." The timing, with the REACH 2018 registration deadline looming, also is worrisome, they suggest.
The European Chemicals Agency has reported previously on non-animal testing approaches that companies are using to comply with data requirements under EU laws, but for the first time the agency offers commentary on the "regulatory applicability" of available alternative methods in a report issued Nov. 22.
According to ECHA's same-day release, significant scientific developments and evolving industry practices over the past decade have reduced...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
